Results 21 to 30 of about 8,517,970 (127)

A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration’s adverse event reporting system databases [PDF]

Frontiers in Immunology
ObjectiveThe study bridge statistical pharmacovigilance signals to clinically actionable insights by systematically characterizing adverse event (AE) patterns associated with ublituximab and identifying previously unrecognized risks.
Jiagnang Cao, Qinguo Shen, Yan Zou
doaj   +4 more sources

Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess [PDF]

Frontiers in Pharmacology
BackgroundHead and neck squamous cell carcinoma (HNSCC) remains a significant global health concern, with treatment outcomes for advanced or metastatic stages being suboptimal despite the availability of various targeted therapies and immunotherapies ...
Weimin Gao, Zhigang Xia, Tingfeng Zhou, Youlin Dong   +3 more
doaj   +4 more sources

Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events [PDF]

Frontiers in Pharmacology
BackgroundTarlatamab is a DLL3-targeted bispecific T-cell engager approved for previously treated extensive-stage small cell lung cancer (ES-SCLC).
Yingyong Ou, Xianxian Zhong, Mei Mei, Xiao Gu, Shanshan Luo, Gaoyu Chen, Xuqin Xie, Desheng Sun   +7 more
doaj   +3 more sources

Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study [PDF]

Frontiers in Medicine
BackgroundLeukotriene receptor antagonists (LTRAs), including montelukast, pranlukast, and zafirlukast, are generally well tolerated and widely used for asthma and allergic rhinitis, but they may cause adverse drug reactions (ADRs).
Youlin Dong, Zhigang Xia, Weimin Gao
doaj   +2 more sources

Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess [PDF]

Frontiers in Pharmacology
BackgroundPulmonary fibrosis is a severe and potentially fatal adverse event, and its association with disease-modifying antirheumatic drugs (DMARDs) has raised long-standing concerns. However, systematic investigations on this topic are lacking.
Xinyue Zhang, Xinhui Wu, Cheng Luo, Chun Yang, Nan Jia, Jiayi He, Qian Chen, Fei Wang   +7 more
doaj   +2 more sources

Real‐World Data Analysis of Vascular and Lymphatic Adverse Events Associated With Antitumor Angiogenesis Drugs: A WHO‐VigiAccess Study

Journal of Clinical Pharmacy and Therapeutics
Antiangiogenic therapy plays a critical role in cancer treatment. This study analyzed vascular and lymphatic adverse events linked to four FDA‐approved agents—aflibercept, bevacizumab, olaratumab, and ramucirumab—using WHO‐VigiAccess data. Disproportionality analysis (ROR and PRR) identified drug‐specific risks, focusing on hypertension, hemorrhage ...
Yue Zu, Lingling Dai, Peng Meng
wiley   +3 more sources

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases [PDF]

Frontiers in Pharmacology
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng, Mengmeng Peng, Qian Guo, Zihan Dang, Baiquan Zhang, Manjuan Li, Manjuan Li, Zixuan Wang, Zixuan Wang, Xuemian Lu, Xuemian Lu, Jie Lin   +11 more
doaj   +2 more sources

Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases [PDF]

Endocrine Connections
Background: Somatrogon, a long-acting recombinant human growth hormone, is used in children with growth hormone deficiency. While clinical trials have shown its safety, real-world post-marketing data are limited, and uncommon or delayed adverse events ...
Mengyuan Cai, Qian Guo, Huqiang Dong, Yabo Wang, Zhongyu Han, Ping Xu   +5 more
doaj   +2 more sources

Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess [PDF]

Frontiers in Pharmacology
PurposeBreast cancer is the most common malignancy in women. Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients rely on endocrine therapy as their fundamental systemic treatment strategy.
Guoqiang Li, Mengqi Yang, Lei Zhang, Xin Li, Xiaoliang Wu, Feng Peng, Yajie Liu   +6 more
doaj   +2 more sources

Safety profile of ticagrelor: an analysis based on literature and database review [PDF]

BMC Cardiovascular Disorders
Objective Ticagrelor, a reversible P2Y12 receptor antagonist, is widely used in acute coronary syndromes (ACS) for its superior efficacy over clopidogrel.
Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu   +3 more
doaj   +2 more sources